Loading...
XNASIMUX
Market cap90mUSD
Jan 14, Last price  
1.00USD
1D
-6.54%
1Q
-35.06%
Jan 2017
-77.01%
IPO
-91.74%
Name

Immunic Inc

Chart & Performance

D1W1MN
XNAS:IMUX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
111.02%
Rev. gr., 5y
%
Revenues
0k
Net income
-94m
L-39.33%
-5,879,000-6,701,000-32,718,000-47,667,000-52,023,000-40,969,000-52,078,000-41,475,000-34,826,000-43,959,000-92,794,000-154,296,000-93,612,000
CFO
-71m
L+8.73%
-7,831,000-9,244,000-28,648,000-40,825,000-49,952,000-35,774,000-40,397,000-43,165,000-28,545,000-46,124,000-83,233,000-65,144,000-70,828,000
Earnings
Jun 11, 2025

Profile

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
URL
https://imux.com/
IPO date
Apr 17, 2014
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
99,334
86,595
Unusual Expense (Income)
NOPBT
(99,334)
(86,595)
NOPBT Margin
Operating Taxes
33,889
Tax Rate
NOPAT
(99,334)
(120,484)
Net income
(93,612)
-39.33%
(154,296)
66.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
853
95,942
BB yield
-1.28%
-215.37%
Debt
Debt current
695
571
Long-term debt
1,278
1,984
Deferred revenue
Other long-term liabilities
Net debt
(44,701)
(113,819)
Cash flow
Cash from operating activities
(70,828)
(65,144)
CAPEX
(334)
(112)
Cash from investing activities
9,462
(9,741)
Cash from financing activities
1,033
96
FCF
(99,253)
(114,098)
Balance
Cash
46,674
116,374
Long term investments
Excess cash
46,674
116,374
Stockholders' equity
(407,129)
(314,241)
Invested Capital
437,394
429,488
ROIC
ROCE
EV
Common stock shares outstanding
44,320
31,819
Price
1.50
7.14%
1.40
-85.37%
Market cap
66,480
49.24%
44,547
-80.32%
EV
21,779
(69,272)
EBITDA
(99,223)
(86,518)
EV/EBITDA
0.80
Interest
1,041
Interest/NOPBT